

## Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

### Listing of Claims

1. (Original) A method of treating vascular depression comprising administering to a subject in need of such treatment a therapeutically effective amount of a cholinesterase inhibitor, in free form or in pharmaceutically acceptable salt form.
2. (Cancelled)
3. (Original) A method according to claim 1 wherein the cholinesterase inhibitor is rivastigmine tartrate (Exelon®), donepezil hydrochloride (Aricept®) or galanthamine hydrobromide (Reminyl®).
4. (Original) A method according to claim 3 wherein the cholinesterase inhibitor is rivastigmine tartrate (Exelon®).
5. (Original) A method according to claim 4 wherein rivastigmine tartrate (Exelon®) is administered at a daily dosage of between 3 mg and 12 mg.
6. (Original) A method according to claim 1 wherein the cholinesterase inhibitor is rivastigmine which is administered transdermally in free base form.
7. (Original) A method according to claim 6 wherein rivastigmine is administered at a dose of 9 mg in a transdermal patch of ~5 cm<sup>2</sup>, once every day.
8. (Original) A method according to claim 6 wherein rivastigmine is administered at a dose of 18 mg in a transdermal patch of ~10 cm<sup>2</sup>, once every day.
9. (Currently amended) A method of treating vascular depression comprising administering to a subject in need of such treatment a [[A]] pharmaceutical composition comprising a pharmaceutically acceptable carrier or diluent and a therapeutically effective amount of: 1) a cholinesterase inhibitor; and 2) an anti-depressant, said cholinesterase inhibitor and anti-depressant being in free form or pharmaceutically acceptable salt form.
10. (Currently amended) A method eomposition according to claim 9 wherein the cholinesterase inhibitor is selected from rivastigmine tartrate (Exelon®), donepezil hydrochloride

(Aricept®) and galanthamine hydrobromide (Reminyl®).

11. (Currently amended) A method composition according to claim 10 wherein the cholinesterase inhibitor is rivastigmine tartrate (Exelon®).

12. (Currently amended) A method composition according to claim 11 wherein the rivastigmine tartrate (Exelon®) is present in an amount between 3 mg and 12 mg.

13. (Currently amended) A method composition systemic transdermal pharmaceutical composition according to claim 9 wherein the cholinesterase inhibitor is rivastigmine in free base form and the composition is in the form of systemic transdermal pharmaceutical composition.

14. (Currently amended) A method composition according to claim 13 wherein rivastigmine is present in an amount of 9 mg in a transdermal patch of ~5 cm<sup>2</sup>.

15. (Currently amended) A method composition according to claim 13 wherein rivastigmine is present in an amount of 18 mg in a transdermal patch of ~10 cm<sup>2</sup>.

16. (Currently amended) A method composition to claim 9 wherein the anti-depressant is selected from selective serotonin reuptake inhibitor (SSRI) [[SSRI]] anti-depressants, serotonin-norepinephrine reuptake inhibitor (SNRI) [[SNRI]] anti-depressants, Monoamine oxidase (MAO) [[MAO]] inhibitor anti-depressants, tricyclic anti-depressants, bupropion hydrochloride (Wellbutrin®) and mirtazapine (Remeron®) Wellbutrin® and Remeron®.

17. (Currently amended) A method composition to claim 9 wherein the cholinesterase inhibitor is selected from rivastigmine tartrate (Exelon®), donepezil hydrochloride (Aricept®) and galanthamine hydrobromide (Reminyl®) and the anti-depressant is selected from paroxetine hydrochloride (Paxil®), fluoxetine hydrochloride (Prozac®), sertraline hydrochloride (Zoloft®), citalopram hydrobromide (Celexa®), escitalopram oxalate (Lexapro®), venlafaxine hydrochloride (Effexor®), phenelzine sulfate (Nardil®), tranylcypromine sulfate (Parnate®), amitriptyline (Elavil®), desipramine hydrochloride (Norpramin®), bupropion hydrochloride (Wellbutrin®) and mirtazapine (Remeron®). Paxil®, Prozac®, Zoloft®, Celexa®, Lexapro®, Effexor®, Nardil®, Parnate®, amitriptyline, Norpramin®, Wellbutrin® and Remeron®.

18. (Currently amended) A method composition according to claim 17 wherein the cholinesterase inhibitor is rivastigmine tartrate (Exelon®) and the anti-depressant is selected from rivastigmine tartrate (Exelon®), donepezil hydrochloride (Aricept®) and galanthamine hydrobromide (Reminyl®) and the anti-depressant is selected from paroxetine hydrochloride

(Paxil®), fluoxetine hydrochloride (Prozac®), sertraline hydrochloride (Zoloft®), citalopram hydrobromide (Celexa®), escitalopram oxalate (Lexapro®), venlafaxine hydrochloride (Effexor®), phenelzine sulfate (Nardil®), tranylcypromine sulfate (Parnate®), amitriptyline (Elavil®), desipramine hydrochloride (Norpramin®), bupropion hydrochloride (Wellbutrin®) and mirtazapine (Remeron®). ~~Paxil®, Prozac®, Zoloft®, Celexa®, Lexapro®, Effexor®, Nardil®, Parnate®, amitriptyline, Norpramin®, Wellbutrin® and Remeron®.~~

19. (Currently amended) A method composition according to claim 18 wherein the rivastigmine tartrate (Exelon®) is present in an amount between 3 mg and 12 mg.

20-32. (Cancelled)